Company Filing History:
Years Active: 2008
Title: **Innovator Spotlight: Daniel Hartman – A Pioneer in Cardiac Treatment**
Introduction
Daniel Hartman, an accomplished inventor based in Brighton, MI, has made significant contributions to the field of pharmaceuticals. With a keen focus on treating acute coronary syndromes, Hartman has been instrumental in developing innovative methods and formulations that have the potential to enhance patient care and outcomes. His dedication and ingenuity are evident in his work, particularly through his patented invention.
Latest Patents
Hartman's notable patent is titled "Pharmaceutical formulations, methods, and dosing regimens for the treatment and prevention of acute coronary syndromes." This invention outlines methods and formulations designed to treat and prevent these medical emergencies effectively. Specifically, it introduces safe and effective doses of an Apolipoprotein A-I Milano:phospholipid complex aimed at reducing and stabilizing atherosclerotic plaque. The patent not only provides innovative pharmaceutical formulations of these complexes but also emphasizes their vital role in improving cardiovascular health.
Career Highlights
Currently, Daniel Hartman is associated with Pfizer Corporation, a leading entity in the pharmaceutical industry known for its commitment to healthcare innovation. Through his role there, Hartman has leveraged his expertise in developing groundbreaking therapeutic solutions that address significant health challenges, particularly in cardiovascular medicine. His singular patent reflects his commitment to addressing the needs of patients experiencing acute coronary syndromes.
Collaborations
Throughout his career, Daniel Hartman has collaborated with notable professionals in his field, including Charles Larry Bisgaier and Narendra D Lalwani. These partnerships reflect a collaborative spirit in research and innovation, as they work collectively to improve treatment options and advance medical knowledge in their field.
Conclusion
Daniel Hartman's work exemplifies the essence of innovation in medicine. His patented formulations and methods represent a significant step forward in the treatment and prevention of acute coronary syndromes. As he continues to work with leading institutions like Pfizer Corporation and collaborate with esteemed colleagues, the impact of his contributions on cardiac health and pharmaceutical advancements will surely resonate in both the scientific community and patient care for years to come.